Piper Sandler downgrades Globe Life to Neutral and cuts price target after Q3 earnings
Piper Sandler lowered its rating on Globe Life to Neutral and reduced the price target to $165 from $200, citing volatility in medical claims. The downgrade followed Globe Life's third‑quarter 2026 results, which showed revenue of $1.6 billion but earnings per share of $4.84, missing the $4.91 estimate. The analyst highlighted concerns over claim severity and irregularity in Medicare supplement business. The stock slipped in pre‑market trading after the downgrade.
Why it matters
The reduced price target and neutral rating may pressure the share price, as investors adjust expectations for future earnings. The downgrade signals heightened risk from medical‑claim volatility, which could affect valuation multiples.
Key facts
- 1Piper Sandler downgraded Globe Life to Neutral from Overweight. investing.com
- 2The firm lowered the price target to $165 from $200. investing.com
- 3Globe Life reported Q3 2026 revenue of $1.6 billion, beating the forecast of $1.56 billion. investing.com
- 4Q3 diluted earnings were $4.84 per share, missing the estimate of $4.91. investing.com
- 5The stock traded at $168.41 with a P/E ratio of 10.97. investing.com
- 6Shares fell 3.4% to $162.69 in pre‑market trading after the downgrade. seekingalpha.com
Open questions
- Two materials give different current share prices: $168.41 and $162.69.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.